2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
72
HER2-positive Breast Cancer
15
Carcinoma, Non-Small-Cell Lung
6
HER2 Positive Metastatic Breast Cancer
4
Breast Diseases
4
Brain Neoplasms
4
HER2 Positive Breast Cancer
3
Advanced Breast Cancer
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
HER2-positive Metastatic Breast Cancer
2
Colorectal Neoplasms
2
Breast Cancer Invasive
2
Breast Cancer Female
2
Solid Tumor
1
Rare Tumour
1
Rare Tumor
1
Pathologic Complete Response
1
Non-squamous NSCLC
1
Non Small Cell Lung
1
Neoplasm Metastasis
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Metastatic Breast Cancer in the Brain
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
HER2-expressing Advanced Solid Tumors
1
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
1
Interventions
Vinorelbine
3
Capecitabine
2
ribociclib
1
pyrotinib
1
Trastuzumab
1
Lapatinib
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Advanced Breast Cancer
×
pyrotinib
×
Clear all
NCT05856383
2023-05-12
HER2-VIP
Zhejiang Cancer Hospital
Recruiting
100 enrolled